戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 as confirmed using the EP2-selective agonist butaprost.
2 ed the inhibitory effects of both PGE(2) and butaprost.
3 lprostone, but not the EP2 receptor agonist, butaprost.
4 EP1R antagonist SC-19220 or the EP2R agonist butaprost.
5 expressions after ICH, which was reversed by butaprost.
6 nd IgG class switching, exogenous PGE(2) and butaprost, a selective EP2 agonist, augmented AID mRNA/p
7 e the PGE(2)-dependent pathway, we show that butaprost, a specific EP2 agonist, stimulates progestero
8                                              Butaprost also induced the activation of Akt, ERK1/2, an
9                                              Butaprost also mimicked the effect of OxPAPC on the regu
10 clic AMP ([cAMP]i) by PGE2, misoprostol, and butaprost and of increases in the intracellular concentr
11                                              Butaprost and ONO-AE1-329, EP(2) and EP(4) receptor agon
12                           The application of butaprost and sulprostone triggered neuropeptide exocyto
13 he effects of specific EP2 and EP3 agonists (butaprost and sulprostone) in cultured trigeminal gangli
14      Agonists of E prostanoid receptors EP2 (butaprost) and EP1/3 (sulprostone) mimicked PGE2, while
15   EP2 prostaglandin receptor activation with butaprost blocks the TGFbeta1-stimulated expression of C
16 and misoprostol, and EP2 R-selective agonist butaprost but not the EP1 R-selective antagonist SC-1922
17 fects were mimicked fully by the EP2 agonist butaprost but only weakly by the EP1/EP3 agonist 17-phen
18                    The selective EP2 agonist butaprost, but neither the EP1/EP3 agonist sulprostone n
19 Treatment with PGE2 or EP2 selective agonist butaprost, but not EP4 agonist CAY10598, increased cAMP
20 icked by the EP2-selective receptor agonist, butaprost, by cAMP activation, and were lost in murine l
21 ngle topical application of the EP2 agonist, butaprost, dose-dependently increased keratinocyte repli
22 nophosphate acetoxymethyl ester mimicked all butaprost effects.
23 n F2alpha (PGF2alpha) (FP receptor agonist), Butaprost (EP2 receptor agonist), and Bimatoprost (a pro
24 stol), EP2 -selective (ONO-AE1-259, AH13205, butaprost-free acid) and EP4 -selective (L-902,688, TCS2
25                     However, an EP2 agonist (butaprost) has no effect on MMP-9 expression, and macrop
26 to beta-arrestin1-dependent EGFR activation, butaprost increased PKA activation, as measured by phosp
27                                              Butaprost induced beta-arrestin1-Src complex formation a
28                        In resting microglia, butaprost induced cAMP formation and altered the mRNA ex
29 monophosphorothioate (R(P)-cAMPS)) decreased butaprost-induced cAMP-response element-binding protein
30 decreased EGFR activation but did not affect butaprost-induced PKA activation, thus indicating that t
31 at the mRNA for the murine EP4 receptor, the butaprost-insensitive PGE2 receptor that couples to Gs,
32 d little effect on membrane current, whereas butaprost methyl ester (an EP2 agonist) mimicked the eff
33 tors, direct addition of sulprostone but not butaprost mimicked PGE2, suggesting that PGE2 engaged EP
34        In contrast, the EP2 receptor agonist butaprost, not the E1/E3 receptor agonist sulprostone, s
35 y finding that PGE2 and misoprostol, but not butaprost or sulprostone, evoked increases in the intrac
36 (2) production, and PGE(2), the EP2 agonist (butaprost) or EP4 agonist (PGE(1) alcohol), was applied.
37 ministration of either EP2-specific agonist, butaprost, or 8-Br-cAMP, a cell-permeable cAMP analog, p
38 the TGFbeta1-stimulated CCN2/CTGF by PGE(2), butaprost, or forskolin is due to p38, ERK, and JNK MAP
39 stone triggered neuropeptide exocytosis, and butaprost sensitized capsaicin responses.
40  not with 10(-6) M PGF2alpha, PGD2, PGI2, or butaprost, suggesting a principal dependence on EP3 Rs.
41 addition of PGE2 or the EP2 receptor agonist butaprost to PMK produced a dose- and time-dependent dec
42 dent inhibition of Ca(2+) signals by PGE2 or butaprost (to activate EP2 receptors selectively), but i
43 hanisms of LPA1, the selective EP2 activator butaprost was administered by intracerebroventricular in
44                     The EP2 specific agonist butaprost was shown to mimic the effect of OxPAPC on the
45 1%) VSMCs, whereas the EP2 receptor agonist, butaprost, was without effect.